{
    "componentChunkName": "component---src-templates-blog-post-js",
    "path": "/posts/e5f31ff2586e11ec9f4bf3dd6631ab51/",
    "result": {"data":{"allMysqlLists":{"edges":[{"node":{"title":"Risdiplam is a life-changing drug for Eleanor, but it comes with $400,000-a-year price tag","status":1,"alt":"Play Video. Duration: 1 minute 37 seconds","src":"https://live-production.wcms.abc-cdn.net.au/81d1b2a703762bd9f38674a25166a909","source":"abc","menu":"au","local_src":"","load_img":"","img_url":"https://live-production.wcms.abc-cdn.net.au/1d7171c26d137214336bb80e390b8131","href":"https://www.abc.net.au/news/2021-12-09/why-risdiplam-should-accessible-for-people-with-sma/100668468","description":"Disability rights activist and science journalist Eleanor Beidatsch explains why life-changing medications, which help people with a degenerative disability, should be made available to all. ","country":"au","create_time":"2021-12-08T13:36:44.000Z","content":"[\"Living with a degenerative disability is difficult, but it's nothing compared to knowing there are life-changing treatments I can't\\u00a0access because I'm too old, and they are too expensive.\", \"I have Spinal Muscular Atrophy or SMA Type 1, a rare and severe genetic condition that affects around 1 in 10,000 people and is carried by 1 in 40.\", \"SMA has four different forms and Type 1 is the second most severe, with most babies dying before they reach the\\u00a0age of two.\", \"The severity of the type\\u00a0is determined by how many copies of a particular gene \\u2014\\u00a0survivor motor neuron or SMN \\u2014\\u00a0a person has.\", \"SMN produces a protein that affects motor neurons and without many copies, it causes muscle weakness and even paralysis.\", \"<div class=\\\"head3\\\">Defying the odds</div>\", \"When I was diagnosed with SMA Type 1 in 1994, my family was told I would die by the age of two and nothing could be done.\", \"SMA is incurable,\\u00a0but I survived against the odds and have lived long enough to see the invention of three treatments making a huge difference to the lives of people living with the condition.\", \"They are Spinraza,\\u00a0also known as Nusinersen,\\u00a0\\u00a0Risdiplam, and Zolgensma.\", \"Risdiplam\\u00a0is the only SMA treatment that's delivered orally.\", \"<img src=\\\"https://live-production.wcms.abc-cdn.net.au/6aa2ae2acfde0a7c2e7f0fde2e552ea5\\\" class=\\\"abcImg\\\"></img>\", \"<div class=\\\"imgText\\\"> Eleanor, with her sister Kirsten (left) and mother Karen, wants Risdiplam to be accessible to more adults like her.\\u00a0</div>\", \"All three increase production of the SMN protein, slowing progression of the disease.\", \"This was amazing news for the SMA community. We\\u00a0had gone from zero to three treatments in only a few short years.\", \"Suddenly the outlook for adults like me was less grim. Until now.\", \"I've been using Risdiplam for almost 18 months, with significant improvements to my physical strength and endurance.\", \"But that could be about to change. In August, the\\u00a0Pharmaceutical Benefits Scheme (PBS) ruled that neither Risdiplam nor Spinraza would be available for people aged over 18.\", \"My treating neurologist, Dr Merrilee Needham, was able to prescribe me Risdiplam with a\\u00a0compassionate exemption because of the severity of my case and at this stage, I still take it for free.\", \"<div class=\\\"head3\\\">Risdiplam, Spinraza, Zolgensma all expensive</div>\", \"But that option isn't available to everyone, and I don't know how long I'll have access to this life-changing medication.\", \"Risdiplam\\u00a0costs\\u00a0more than $400,000\\u00a0a year and it's taken for a person's whole life.\", \"The drugs are so expensive because of the high cost to trial and manufacture the precision medication. When a novel drug does work and gets approved, costs can be\\u00a0substantial to cover the money spent in failed trials and future research.\", \"Spinraza costs more than $1 million in its first year and Zolgensma \\u2014 described as\\u00a0the most expensive drug in the world\\u00a0\\u2014 is worth more than\\u00a0$2.8 million for a one-off injection.\", \"Risdiplam trials in Australia are small and no results on its effectiveness in adults have been published yet. The trials show the drug works for children, but only a few adults have access to it at this stage.\", \"Dr Steve Wilton, a neuromuscular disease researcher from Murdoch University, is concerned the cost of the drugs will be a long-term issue.\", \"\\\"The\\u00a0cost\\u00a0of these drugs [is]\\u00a0horrendous,\\\" Dr Wilton said.\", \"\\\"What we're trying to do is improve the quality of life.\", \"\\\"In SMA what you're trying to do is turn a Type 1 Into Type 2.\", \"<img src=\\\"https://live-production.wcms.abc-cdn.net.au/a8ae71495dc1440e1fbe1e301adae3f4\\\" class=\\\"abcImg\\\"></img>\", \"<div class=\\\"imgText\\\"> Murdoch University's Steve Wilton, pictured with fellow researchers Loren Flynn and Sue Fletcher, is worried about the cost of the drugs.(Supplied: Murdoch University)</div>\", \"\\\"I don't know what's going to happen when you've got kids being treated from six months and still going at 18 years, you can't stop the treatment.\\\"\", \"He describes Risdiplam as \\\"promising\\\" and hopes it will be made available to everyone who needs it.\", \"<div class=\\\"head3\\\">More data on adults needed</div>\", \"Dr Needham says Risdiplam should be available to patients regardless of their age.\", \"\\\"Even though the disease is slower in adults, it should still work,\\\" she said.\", \"\\\"Treatment shouldn't be dictated by age;\\u00a0if it works, it should be available for everyone.\", \"<img src=\\\"https://live-production.wcms.abc-cdn.net.au/db5281f7bc2bda2e7c1e78bc00a1a3d8\\\" class=\\\"abcImg\\\"></img>\", \"<div class=\\\"imgText\\\"> Dr Merrilee Needham says it is \\\"heartbreaking\\\" that not all patients can access the treatment.\\u00a0(Supplied: Josh Wells)</div>\", \"\\\"Unless I inherit them on-treatment, it's very hard to access treatment for adults in the current system.\", \"\\\"These patients face a future that they will decline over time, it's the natural progression \\u2026 [yet] there's a treatment that can impact that, and not being able to access that is heartbreaking.\\\"\", \"Julie Cini is the CEO of\\u00a0advocacy group Spinal Muscular Atrophy Australia (SMAA) and\\u00a0lost both of her children, Montanna and Zarlee, to the degenerative disease when they were only 10 and 12 months old respectively.\", \"<img src=\\\"https://live-production.wcms.abc-cdn.net.au/dd3aed5e3f0afb340ec88a77a87219fe\\\" class=\\\"abcImg\\\"></img>\", \"<div class=\\\"imgText\\\"> Julie Cini founded SMAAafter losing both her children Zarlee (left) and Montanna (right) to Spinal Muscular Atrophy in 2007\\u00a0and 2005.(ABC News)</div>\", \"Ms Cini says the PBS bases its\\u00a0decision on the available data and there isn't enough information on the effectiveness in adults yet.\", \"\\\"That is the crux of the reason why over 18s don't have access to Risdiplam here in Australia,\\\" she said.\\u00a0\", \"<div class=\\\"head3\\\">Gene therapy drugs a game changer</div>\", \"Perron Institute scientist\\u00a0Loren Flynn researched possible treatments for SMA through the University of Western Australia in the days before Spinraza came onto the market.\", \"<img src=\\\"https://live-production.wcms.abc-cdn.net.au/a777993ec73c3c7ea7db60b4fc4a0d89\\\" class=\\\"abcImg\\\"></img>\", \"<div class=\\\"imgText\\\"> Dr\\u00a0Flynn\\u00a0has been involved in researching treatments for SMA.</div>\", \"Dr Flynn said\\u00a0the improvements in treatment changed significantly in a short time.\", \"\\\"Spinraza was the first treatment approved that would have an impact on the disease progression.\", \"\\\"Since then, there's the gene therapy drugs, Zolgensma [and]\\u00a0now with Risdiplam, that's changed the treatment space entirely.\\\"\", \"Dr Flynn believes the early results for Risdiplam in children show promise.\", \"\\\"It's more comfortable to take, there are less side effects,\\\" she said.\", \"\\\"There have been clinical improvements for adults receiving Spinraza [and]\\u00a0clinical trials to test Risdiplam in adults are ongoing.\\\"\", \"Dr Flynn said as technology to manufacture and deliver\\u00a0precision medication improved, the cost of the drugs would go down.\", \"<img src=\\\"https://live-production.wcms.abc-cdn.net.au/f6c33a64e5e40f41c77e84a4eea06515\\\" class=\\\"abcImg\\\"></img>\", \"<div class=\\\"imgText\\\"> Julie Cini says more information is needed about\\u00a0Risdiplam's effectiveness in adults.\\u00a0(ABC News: Supplied)</div>\", \"SMAA is\\u00a0working with the companies to provide relevant data on the trials, which are passed onto the PBS.\", \"<div class=\\\"head3\\\">Risdiplam decision due next year</div>\", \"The PBS will examine the data and make another decision on the availability of Risdiplam for adults in 2022.\", \"What's clear from the different trials is that treatment for SMA is not the same for adults as it is for children.\", \"This is something Dr Lauren Sanders, Associate Professor of Neurology at St\\u00a0Vincent Hospital in Melbourne,\\u00a0is working to address. She is a paid member on advisory committees for Roche and Biogen.\", \"She remembers how it felt hearing the first Spinraza results in 2016.\", \"Research from Germany shows Spinraza is improving the quality of life in adults too.\", \"\\\"I've been a lot more convinced by the data that's come out of Germany,\\\" she says.\", \"In America and Germany, adults have open access to Risdiplam, and efforts are underway to obtain data from those countries.\", \"\\\"It won't be as strong an evidence base as if it had been a proper clinical trial but certainly it will give us an indicator of effectiveness and safety,\\\" Dr Sanders said.\", \"Dr Sanders is also consulting the adult SMA community in Australia to develop a standardised treatment.\", \"Hopefully for people like me, the trial results will speak for themselves, and we can continue to improve our quality of life, even if the results are small.\", \"ABC is partnering with\\u00a0International Day of People with Disability\\u00a0to celebrate the contributions and achievements of the 4.4 million Australians with disability.\"]","href_hash":"e5f31ff2586e11ec9f4bf3dd6631ab51"}}]}},"pageContext":{"slug":"e5f31ff2586e11ec9f4bf3dd6631ab51"}},
    "staticQueryHashes": ["3649515864","764694655"]}